Latest Imugene News & Updates

See the latest news and media coverage for Imugene. We track all announcements, press releases, and industry mentions in real time, all in one place.

Imugene

Clinical-stage cell therapy company

Last updated October 5

Latest news about Imugene

In short: Imugene reported strong azer-cel trial responses, secured funding, and advanced its CAR-T pipeline with FDA fast-track status.

October 5 Imugene

Cohort 3 showed 71% ORR. Combined ORR is 75%, demonstrating consistent efficacy across CAR-T and BTKi populations.

July 27 Imugene

Both follicular lymphoma patients responded to azer-cel and BTKi therapy after prior relapse.

July 1 Imugene

Both evaluable patients in the BTKi cohort responded, including the first Mantle Cell Lymphoma patient after BTKi resistance.

June 30 Imugene

First patient in BTKi cohort achieved complete response at Day 28; four patients dosed and enrolment continues across 15 sites.

July 27 Herald Sun

Imugene (ASX:IMU): Biotech Stock Rockets as FDA Fast Track News Ignites Investor Excitement...

Never miss news about Imugene

Track Imugene and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Browse news for competitors to Imugene and other trending companies.